Evangelos K Oikonomou1, Theodoros I Repanas2, Christos Papanastasiou3, Damianos G Kokkinidis3, Michael Miligkos4, Attila Feher5, Dipti Gupta6, Polydoros N Kampaktsis7. 1. Society of Junior Doctors, Athens, Greece; National and Kapodistrian University of Athens, Faculty of Medicine, Athens, Greece. Electronic address: evoikonomou@sni.gr. 2. Society of Junior Doctors, Athens, Greece. 3. Society of Junior Doctors, Athens, Greece; Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece. 4. Society of Junior Doctors, Athens, Greece; Laboratory of Biomathematics, University of Thessaly School of Medicine, Larissa, Greece. 5. New York Presbyterian Hospital/Weill Cornell Medical College, Department of Medicine, NY, USA. 6. Memorial Sloan Kettering Cancer Center, Cardiology Service, New York, USA. 7. Society of Junior Doctors, Athens, Greece; New York Presbyterian Hospital/Weill Cornell Medical College, Department of Medicine, NY, USA.
Abstract
BACKGROUND: In-hospital acquired thrombocytopenia (TP) is relatively common among patients hospitalized with acute coronary syndromes (ACS). However, its effect on short-term and long-term outcomes has yet to be reviewed systematically. METHODS: We conducted a systematic review and meta-analysis of clinical studies assessing the relationship between new-onset in-hospital TP and adverse outcomes among ACS patients. MEDLINE, Scopus and the Cochrane Library were searched for eligible studies published before March 20, 2016. RESULTS: Ten studies reporting on a total of 142,161 ACS patients were identified. 8133 patients showed evidence of new-onset TP during the course of their hospitalization. Compared with patients with normal platelet counts, patients with new-onset TP had a prolonged in-hospital stay, significantly higher risk of both short-term mortality (<30days) (Odds ratio (OR) [95% confidence interval (CI)]: 5.58 [3.63-8.57]) and late death (6months to 1year) (OR [95% CI]: 3.45 [2.35-5.07]), as well as a significantly higher risk of major bleeding events in the first 30days (OR [95% CI]: 6.93 [5.13-9.38]). In addition, risk for other secondary cardiovascular endpoints, including recurrent myocardial infarction, stroke, in-hospital heart failure, stent thrombosis and unplanned revascularization was also significantly higher in the TP versus the no TP group. CONCLUSIONS: Development of TP during the in-hospital management of ACS patients is a significant predictor of both short- and long-term adverse events, including mortality. In the light of this evidence, clinicians should be cautious and closely monitor abnormal platelet counts that present early following an ACS.
BACKGROUND: In-hospital acquired thrombocytopenia (TP) is relatively common among patients hospitalized with acute coronary syndromes (ACS). However, its effect on short-term and long-term outcomes has yet to be reviewed systematically. METHODS: We conducted a systematic review and meta-analysis of clinical studies assessing the relationship between new-onset in-hospital TP and adverse outcomes among ACS patients. MEDLINE, Scopus and the Cochrane Library were searched for eligible studies published before March 20, 2016. RESULTS: Ten studies reporting on a total of 142,161 ACS patients were identified. 8133 patients showed evidence of new-onset TP during the course of their hospitalization. Compared with patients with normal platelet counts, patients with new-onset TP had a prolonged in-hospital stay, significantly higher risk of both short-term mortality (<30days) (Odds ratio (OR) [95% confidence interval (CI)]: 5.58 [3.63-8.57]) and late death (6months to 1year) (OR [95% CI]: 3.45 [2.35-5.07]), as well as a significantly higher risk of major bleeding events in the first 30days (OR [95% CI]: 6.93 [5.13-9.38]). In addition, risk for other secondary cardiovascular endpoints, including recurrent myocardial infarction, stroke, in-hospital heart failure, stent thrombosis and unplanned revascularization was also significantly higher in the TP versus the no TP group. CONCLUSIONS: Development of TP during the in-hospital management of ACS patients is a significant predictor of both short- and long-term adverse events, including mortality. In the light of this evidence, clinicians should be cautious and closely monitor abnormal platelet counts that present early following an ACS.
Authors: Homam Ibrahim; Robert C Schutt; Bashar Hannawi; Timothy DeLao; Colin M Barker; Neal S Kleiman Journal: J Am Coll Cardiol Date: 2014-11-10 Impact factor: 24.094
Authors: M W McClure; S D Berkowitz; R Sparapani; R Tuttle; N S Kleiman; L G Berdan; A M Lincoff; J Deckers; R Diaz; K R Karsch; D Gretler; M Kitt; M Simoons; E J Topol; R M Califf; R A Harrington Journal: Circulation Date: 1999-06-08 Impact factor: 29.690
Authors: Diaa A Hakim; George D Dangas; Adriano Caixeta; Eugenia Nikolsky; Alexandra J Lansky; Jeffrey W Moses; Bimmer Claessen; Elias Sanidas; Harvey D White; E Magnus Ohman; Steven V Manoukian; Martin Fahy; Roxana Mehran; Gregg W Stone Journal: Am Heart J Date: 2011-02 Impact factor: 4.749
Authors: C L Bennett; J M Connors; J M Carwile; J L Moake; W R Bell; S R Tarantolo; L J McCarthy; R Sarode; A J Hatfield; M D Feldman; C J Davidson; H M Tsai Journal: N Engl J Med Date: 2000-06-15 Impact factor: 91.245
Authors: Axel De Labriolle; Laurent Bonello; Gilles Lemesle; Probal Roy; Daniel H Steinberg; Zhenyi Xue; William O Suddath; Lowell F Satler; Kenneth M Kent; Augusto D Pichard; Joseph Lindsay; Ron Waksman Journal: Eur Heart J Date: 2010-01-19 Impact factor: 29.983
Authors: S Selleng; B Malowsky; U Strobel; A Wessel; T Ittermann; H-G Wollert; T E Warkentin; A Greinacher Journal: J Thromb Haemost Date: 2009-09-28 Impact factor: 5.824
Authors: Bala Pushparaji; Teodora Donisan; Dinu V Balanescu; Nicolas Palaskas; Peter Kim; Juan Lopez-Mattei; Mehmet Cilingiroglu; Saamir A Hassan; Konstantinos Dean Boudoulas; Konstantinos Marmagkiolis; Ludhmila Abrahao Hajjar; Cezar A Iliescu Journal: Curr Oncol Rep Date: 2021-09-27 Impact factor: 5.075